Ultrasound Imaging for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a special computer-analyzed ultrasound can accurately measure pancreatic cancer that has spread to the liver, similar to a typical CT scan with contrast dye. It uses an ultrasound imaging technique to compare its results with those from a routine CT scan. The trial seeks participants with pancreatic ductal adenocarcinoma (PDAC) or similar cancers that have metastasized to the liver and are already scheduled for a CT scan. As an unphased trial, this study offers participants the chance to contribute to innovative imaging research that could enhance cancer diagnostics.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this ultrasound imaging technique is safe for measuring PDAC tumors?
Research has shown that ultrasound imaging is generally safe. For example, endoscopic ultrasound, which uses a special tube to examine the body, has a high success rate with no reported deaths. Although some patients experienced pancreatitis, or swelling of the pancreas, this occurrence is rare.
Overall, ultrasound methods used to diagnose and treat pancreatic cancer have been well-tolerated. This suggests that using ultrasound for imaging in this trial is likely safe for participants.12345Why are researchers excited about this trial?
Researchers are excited about the new ultrasound imaging technique for pancreatic cancer because it offers a unique non-invasive way to monitor the disease. Unlike standard methods like contrast-enhanced CT scans, this research ultrasound can potentially provide more frequent and detailed insights without the need for radiation exposure. This technique could allow for better tracking of tumor changes over time, helping doctors tailor treatments more effectively and improve patient outcomes.
What evidence suggests that this ultrasound imaging technique is effective for measuring PDAC tumors in the liver?
Research has shown that ultrasound imaging is a promising tool for managing pancreatic cancer. Studies have found it effective in diagnosing and treating this cancer, often with high success rates. In some patients, ultrasound significantly reduced the blood supply to tumors. Additionally, ultrasound techniques are usually less invasive and more affordable than traditional methods. In this trial, participants will undergo research ultrasound (rUS1) to measure tumor size. Early results suggest that ultrasound could reliably replace CT scans for certain tasks.26789
Who Is on the Research Team?
Kinh Gian Do, MD, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with pancreatic ductal adenocarcinoma (PDAC) or gastrointestinal (GI) adenocarcinoma that has spread to the liver. They must be scheduled for a routine CT scan. People can't join if they can't handle IV contrast, have very small liver metastases, or if their liver is more than half taken up by tumors.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Initial Imaging
Participants undergo research ultrasound (rUS1) within three days of their routine contrast-enhanced CT scan (CECT)
Follow-up Imaging
A subset of participants undergo a second research ultrasound (rUS2) at 3-4 weeks after rUS1
Follow-up
Participants are monitored for safety and effectiveness after imaging procedures
What Are the Treatments Tested in This Trial?
Interventions
- Ultrasound Imaging Technique
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor